| A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators. | |
| | |
MedLine Citation:
|
PMID: 8857004 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Several relatively small randomized trials have shown that primary angioplasty results in a better short-term outcome than thrombolytic therapy in patients with acute myocardial infarction. These results, however, have not been duplicated other than in investigational trials. METHODS: We compared mortality during hospitalization and long-term mortality, as well as the use of resources, among 1050 patients in a primary-angioplasty group and 2095 patients in a thrombolytic-therapy group. Patients were selected from the Myocardial Infarction Triage and Intervention Project Registry cohort of 12,331 consecutive patients admitted with acute myocardial infarction to 19 Seattle hospitals between 1988 and 1994. Because of the potential for selection bias, several subgroup analyses were performed that included patients eligible for thrombolysis, high-risk patients, and patients in the primary-angioplasty group who were treated at hospitals with high volumes of angioplasty. RESULTS: There was no significant difference in mortality during hospitalization or long-term follow-up between patients in the thrombolytic-therapy group and those in the primary-angioplasty group (mortality during hospitalization, 5.6 percent and 5.5 percent, respectively; P=0.93; adjusted hazard ratio for the risk of death within three years after primary angioplasty, 0.95; 95 percent confidence interval, 0.8 to 1.2). There was also no significant difference in mortality between high-risk subgroups of patients in the two treatment groups. The rates of procedures and costs were lower among patients in the thrombolytic-therapy group both at the time of hospital discharge and after three years of follow-up (30 percent fewer coronary angiograms, 15 percent fewer coronary angioplasties, and 13 percent lower costs after three years of follow-up). CONCLUSIONS: In a community setting, we observed no benefit in terms of either mortality or the use of resources with a strategy of primary angioplasty rather than thrombolytic therapy in a large cohort of patients with acute myocardial infarction. |
| | |
Authors:
|
N R Every; L S Parsons; M Hlatky; J S Martin; W D Weaver |
Related Documents
:
|
11113044 - Percutaneous coronary intervention in the current era compared with 1985-1986: the nati... 19172964 - The effects of location and race on the performance of cardiac procedures. 15886794 - Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in ... 2360504 - Percutaneous cardiopulmonary bypass support in the catheterization laboratory: techniqu... 15614124 - Sex differences in the myocardial inflammatory response to acute injury. 12358164 - Capture of atrial fibrillation reduces the atrial defibrillation threshold. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: The New England journal of medicine Volume: 335 ISSN: 0028-4793 ISO Abbreviation: N. Engl. J. Med. Publication Date: 1996 Oct |
Date Detail:
|
Created Date: 1997-01-16 Completed Date: 1997-01-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1253-60 Citation Subset: AIM; IM |
Affiliation:
|
Northwest Health Services Research and Development Field Program, Seattle Veterans Affairs Medical Center, Seattle, WA 98102, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary*
/
economics Cohort Studies Female Fibrinolytic Agents / therapeutic use Hospital Costs Humans Length of Stay Male Middle Aged Myocardial Infarction / drug therapy*, mortality, therapy* Proportional Hazards Models Randomized Controlled Trials as Topic Registries Survival Analysis Thrombolytic Therapy* / economics Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
HS08362/HS/AHRQ HHS; R01 HL38454/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents |
| Comments/Corrections | |
Comment In:
|
N Engl J Med. 1997 Apr 10;336(15):1103; author reply 1104
[PMID:
9091814
]
N Engl J Med. 1997 Apr 10;336(15):1103-4; author reply 1104 [PMID: 9091815 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Semantic distance and single cue use in category search.
Next Document: The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma.